Mobidiag
Mobidiag is a Finnish molecular diagnostics company that developed the proprietary Novodiag platform for automated, rapid detection of infectious diseases including gastrointestinal, respiratory, and sexually transmitted infections, serving clinical laboratories and healthcare providers before being acquired by Hologic.
- Company typePrivate
- Founded2000
- HeadquartersEspoo, Finland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mobidiag does
Mobidiag is a Finnish molecular diagnostics company, founded in 2000 and headquartered in Espoo, Finland, that developed and commercialized rapid diagnostic solutions for infectious disease detection. The company's core offering centered on the proprietary Novodiag® System, a molecular diagnostics platform designed for automated detection of infectious pathogens including gastrointestinal, respiratory, and sexually transmitted infections. The platform utilized random-access molecular testing technology to deliver Walk-Away simplicity for clinical laboratories, with the Novodiag® Direct cartridge-based sub-product enabling direct pathogen detection from patient samples without extensive sample preparation, providing results in approximately 1-2 hours.
The company's go-to-market targeted healthcare providers and diagnostic laboratories requiring rapid infectious disease testing, with particular focus on the STD diagnostics segment aligned with a market projected to reach $17.52 billion by 2030. Mobidiag operated as a venture-backed private company, raising approximately $74 million across multiple funding rounds between 2016 and 2020 from investors including the European Investment Bank, Business Finland, Autobio Diagnostics, and Springvest. The company was acquired by Hologic, a US-based women's health diagnostics company, though the Novodiag product line was subsequently discontinued from Hologic's molecular diagnostics portfolio, suggesting a complex post-acquisition outcome. No publicly disclosed pricing, revenue figures, or detailed customer information is available in the provided sources.
Mobidiag's technology was differentiated by its novel method architecture for automated molecular diagnostics, emphasizing point-of-need testing capabilities and rapid turnaround times compared to traditional diagnostic methods. The cartridge-based consumable model would have generated recurring revenue from installed instrument bases in clinical settings, though the specific revenue mechanics, pricing structure, and commercial scale are not documented in available sources.
Mobidiag firmographics
Firmographics- Name
- Mobidiag
- Legal name
- Mobidiag
- Website
- https://mobidiag.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Mobidiag is a Finnish molecular diagnostics company that developed the proprietary Novodiag platform for automated, rapid detection of infectious diseases including gastrointestinal, respiratory, and sexually transmitted infections, serving clinical laboratories and healthcare providers before being acquired by Hologic.
- Ownership category
- akta.pro rank
Mobidiag industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
- akta.pro secondary industries
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
Keywords
Where Mobidiag is headquartered
LocationHeadquarters
- HQ city
- Espoo
- HQ country
- Finland
- HQ region
- Europe
Markets served
Mobidiag business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Mobidiag product offering
Product offeringCore offering
Mobidiag develops and commercializes the Novodiag molecular diagnostics platform for rapid detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. The portfolio includes the Novodiag System instrument and Novodiag Direct cartridge-based tests, which provide automated random-access molecular testing with results in approximately 1-2 hours directly from patient samples.
Product overview
Mobidiag offers a unified molecular diagnostics platform centered on the Novodiag® system. The portfolio consists of the core Novodiag® instrument platform and the Novodiag® Direct cartridge-based test. The Novodiag® Direct tests are designed for rapid, point-of-need detection of infectious pathogens including gastrointestinal, respiratory, and sexually transmitted infections. The system utilizes random-access molecular testing technology enablingWalk-Away simplicity for clinical laboratories.
Differentiator
Problem solved
Functional benefit
Brands
- Novodiag: Molecular diagnostics platform for rapid infectious disease testing
Products and services
- Novodiag System A rapid molecular diagnostic testing platform designed for automated detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. Built on random-access molecular testing technology providing walk-away simplicity for clinical laboratories.
- Novodiag Direct A cartridge-based molecular test enabling direct detection of pathogens from patient samples without extensive sample preparation, providing results in approximately 1-2 hours. Targeted at clinical laboratories and point-of-need settings for rapid infectious disease diagnosis.
Companies that use Mobidiag
Customer profileSegments1 record
Ideal customer profiles2 records
Mobidiag technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Mobidiag partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Mobidiag competitors and assessment
Company assessmentEmerging players
- Seegene: Seegene develops multiplex molecular diagnostics with a high-menu syndromic approach similar to Mobidiag's strategy, serving respiratory, GI, and STI testing markets.
- T2 Biosystems: T2 develops molecular diagnostics for infectious disease, including sepsis and resistant pathogens, partially overlapping with Mobidiag's infectious disease focus.
- Curetis (OpGen): Curetis developed the Unyvero molecular cartridge-based platform for severe infectious disease diagnostics — a comparable European molecular Dx peer with a similar cartridge/instrument model.
Direct peers
- Cepheid (Danaher): Cepheid's GeneXpert system is the leading molecular POCT platform for infectious disease detection — same product category, same customer base (clinical labs and hospitals), and same cartridge-based assay model as Mobidiag's Novodiag.
- bioMérieux (BioFire): BioFire FilmArray panels are a direct competitor in syndromic molecular infectious disease testing (respiratory, GI), with comparable turnaround times and a similar clinical-laboratory go-to-market.
Broad incumbents
- Roche Diagnostics: Roche's cobas Liat system is a molecular POCT platform for infectious disease, and Roche also owns GenMark — directly comparable technology in the same point-of-care molecular diagnostics category.
- Abbott Diagnostics: Abbott's ID NOW and m-PIMA platforms compete in rapid molecular POCT for infectious diseases, addressing the same hospitals, urgent-care, and clinical-lab customers as Mobidiag.
- Hologic: Hologic acquired Mobidiag and operates the Panther Fusion molecular diagnostics system, making it both an acquirer and a peer in the molecular infectious disease testing space.
- QIAGEN: QIAGEN offers sample-to-result molecular testing solutions (QIAstat-Dx) for syndromic infectious disease detection, directly comparable to Mobidiag's cartridge-based approach.
- QuidelOrtho: QuidelOrtho markets Sofia and other rapid infectious disease diagnostics and is expanding into molecular — overlapping with Mobidiag's respiratory and STI testing focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Mobidiag social profiles
Digital presenceMobidiag financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mobidiag leadership team
Management profileNumber of profiles
Profiles3 records
Mobidiag funding detail
Funding detailFunding overview
Funding rounds9 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mobidiag M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mobidiag
What does Mobidiag do?
Mobidiag develops and commercializes the Novodiag molecular diagnostics platform for rapid detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. The portfolio includes the Novodiag System instrument and Novodiag Direct cartridge-based tests, which provide automated random-access molecular testing with results in approximately 1-2 hours directly from patient samples.
Is Mobidiag a public or private company?
Mobidiag is a private company. It is classified as corporate owned and is currently acquired.
When was Mobidiag founded?
Mobidiag was founded in 2000. It employs 51 to 100 people.
Where is Mobidiag based?
Mobidiag is headquartered in Espoo, Finland, in the Europe region.
Who are Mobidiag's main competitors?
Emerging players on record are Seegene, T2 Biosystems and Curetis (OpGen). Direct peers are Cepheid (Danaher) and bioMérieux (BioFire). Broad incumbents are Roche Diagnostics, Abbott Diagnostics, Hologic, QIAGEN and QuidelOrtho.
Does Mobidiag have an API?
No public API is recorded for Mobidiag.
What industry is Mobidiag in?
Mobidiag's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 621511 and its SIC code is 2835.